pentoxifylline has been researched along with Adenocarcinoma Of Kidney in 8 studies
Excerpt | Relevance | Reference |
---|---|---|
"Patients with disseminated renal cell carcinoma were treated with continuous infusion of 18 x 10(6) IU/m2/24 h for 4 days followed by 3 days without treatment, for 4 consecutive weeks." | 2.68 | The effects of oral pentoxifylline on interleukin-2 toxicity in patients with metastatic renal cell carcinoma. ( Anderson, JA; Edwards, MJ; Harty, JI; Knott, AW; Woodcock, TM, 1995) |
"Pentoxifylline (PTX) is a methylxanthine which reduces IL-2 toxicity in animals." | 2.67 | Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. ( Benyunes, MC; Bianco, JA; Fefer, A; Neubauer, MA; Slattery, JT; Thompson, JA, 1994) |
" When PTX was used in combination with TNF-alpha, the level of TNF-alpha mRNA induced by TNF-alpha was markedly reduced." | 1.29 | Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. ( Bonavida, B; Mizutani, Y; Nio, Y; Yoshida, O, 1994) |
"Pentoxifylline (PTX) is a methylated xanthine that has been shown to reduce the toxicity of Interleukin-2 (IL-2) therapy in animal models, possibly by inhibiting secretion of tumor necrosis factor-alpha." | 1.29 | The effects of pentoxifylline on the generation of human lymphokine-activated killer cell cytotoxicity. ( Benyunes, MC; Bianco, JA; Fefer, A; Lindgren, CG; Shields, AF; Thompson, JA, 1993) |
"Treatment of patients with metastatic renal cell carcinoma with high-dose interleukin-2 (IL-2) administered as continuous intravenous (CIV) infusion or as bolus injection results in response rates of 15% to 30%; however, toxicities with these regimens have been severe." | 1.29 | High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. ( Shulman, KL; Stadler, WM; Vogelzang, NJ, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (87.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (12.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cohen, JD | 1 |
Tham, KY | 1 |
Mastrandrea, NJ | 1 |
Gallegos, AC | 1 |
Monks, TJ | 1 |
Lau, SS | 1 |
Anderson, JA | 1 |
Woodcock, TM | 1 |
Harty, JI | 1 |
Knott, AW | 1 |
Edwards, MJ | 1 |
Thompson, JA | 3 |
Bianco, JA | 3 |
Benyunes, MC | 3 |
Neubauer, MA | 1 |
Slattery, JT | 1 |
Fefer, A | 3 |
Mizutani, Y | 1 |
Bonavida, B | 1 |
Nio, Y | 1 |
Yoshida, O | 1 |
Lindgren, CG | 1 |
Shields, AF | 1 |
Shulman, KL | 1 |
Stadler, WM | 2 |
Vogelzang, NJ | 2 |
Rini, BI | 1 |
Spielberger, RT | 1 |
Ratain, MJ | 1 |
1 review available for pentoxifylline and Adenocarcinoma Of Kidney
Article | Year |
---|---|
Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
Topics: Carcinoma, Renal Cell; Ciprofloxacin; Clinical Trials as Topic; Drug Therapy, Combination; Humans; I | 1993 |
3 trials available for pentoxifylline and Adenocarcinoma Of Kidney
Article | Year |
---|---|
The effects of oral pentoxifylline on interleukin-2 toxicity in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Carcinoma, Renal Cell; Humans; Interleukin-2; Kidney Neoplasms; Nausea; Pentox | 1995 |
Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Ciprofloxacin; F | 1994 |
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans | 1998 |
4 other studies available for pentoxifylline and Adenocarcinoma Of Kidney
Article | Year |
---|---|
cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Topics: Animals; Benzenesulfonates; Bucladesine; Carcinoma, Renal Cell; Cell Line; Cyclin D1; Cyclin-Depende | 2011 |
Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization.
Topics: Carcinoma, Renal Cell; Cisplatin; Down-Regulation; Drug Resistance; Drug Therapy, Combination; Human | 1994 |
The effects of pentoxifylline on the generation of human lymphokine-activated killer cell cytotoxicity.
Topics: Administration, Oral; Carcinoma, Renal Cell; Cytotoxicity, Immunologic; Humans; Immunologic Factors; | 1993 |
High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
Topics: Adjuvants, Immunologic; Adult; Aged; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Human | 1996 |